We provide the proof of concept that liver-targeted anti-Angptl4 ASO treatment strongly attenuates hyperlipidemia and atherosclerosis development, and combined Angptl3/4 silencing has added lipid-lowering benefit. Here, ANGPTL4 is linked to hyperlipidemia.